Vous possédez un compte ?
Connectez-vous pour payer plus vite.
Chargement en cours...
mai 2024
juin 2024
Découvre pourquoi tu devrais commencer ton aventure probiotiques avec Bio-K+.
Nos formules scientifiquement étudiées sont conçues pour soutenir votre parcours unique de bien-être
Bad breath is caused primarily by volatile sulfur compounds produced by bacteria on the tongue. Oral probiotics are being studied for their potential to reduce VSC-producing bacteria at the source. This page reviews the research on probiotics for bad breath.
Halitosis originates primarily from volatile sulfur compounds produced by anaerobic bacteria, including Solobacterium moorei, Fusobacterium nucleatum, and Treponema denticola on the tongue dorsum. In most adults, 90% of bad breath is oral in origin; in a smaller subset, malodor has a digestive or systemic cause. The rationale for studying probiotics: if VSC-producing bacteria can be competitively suppressed, the source of malodor — not just its masking — might be addressed.
In a balanced oral microbiome, commensal bacteria including Streptococcus salivarius compete with VSC-producing anaerobes for adhesion sites; when commensal populations are depleted, anaerobic species proliferate. Certain Streptococcus and Lactobacillus strains produce bacteriocins that target malodor-associated anaerobes, potentially reducing VSC production at its source. Karbalaei et al. (PMC, 2021, cited 60) identified Lactobacillus, Streptococcus, and Weissella as the genera with the most published evidence.
Streptococcus salivarius K12 (BLIS K12) has the most published halitosis research — it produces salivaricin A and B, inhibiting VSC-producing species including Solobacterium moorei and certain Fusobacterium strains. Lactobacillus salivarius has been studied for tongue coat and salivary VSC levels, with several studies reporting measurable reductions. Weissella cibaria produces hydrogen peroxide unfavorable to Fusobacterium nucleatum, identified by Karbalaei et al. as a key VSC-producing species.
A randomized double-blind study on S. salivarius K12 lozenges reported 85% of participants showed significant reductions in halitosis-associated bacteria versus 30% in the placebo group (Karbalaei et al., PMC, 2021). Multiple trials over 2 to 12 weeks found statistically significant reductions in VSC levels and improved organoleptic scores. Reviewers concluded probiotic use may alleviate halitosis through competitive exclusion and bacteriocin production, while noting study quality and short follow-up limit definitive conclusions.
Most halitosis probiotic trials are small (10 to 50 participants) and short (2 to 8 weeks); it is not established whether VSC reductions persist after the probiotic course ends. Bad breath has multiple potential causes: tongue coat, gum disease, dry mouth, post-nasal drip, and GERD. No single probiotic strain addresses all of them. Oral probiotics are best considered a complement to professional dental hygiene, tongue cleaning, and treatment of any underlying condition.
For a subset of people, persistent bad breath originates in the digestive tract: GERD can cause malodor from stomach acid, while gut dysbiosis may contribute to hydrogen sulfide production. In these cases, oral probiotic lozenges are unlikely to address the root cause. A gut-targeted probiotic that contributes to intestinal flora health may be relevant for people with a digestive dimension to their breath concerns. A healthcare professional can help distinguish oral from gut-origin halitosis.
Bio-K+'s three proprietary strains — Lacticaseibacillus casei LBC80R®, Lacticaseibacillus rhamnosus CLR2®, and Lactobacillus acidophilus CL1285® — are formulated for gut health and backed by 16 published clinical trials across 45+ peer-reviewed publications, developed over more than 30 years. Bio-K+ makes no claim that its products address bad breath; its probiotic products contribute to intestinal flora health.
Published research suggests certain oral probiotic strains — particularly Streptococcus salivarius K12 (BLIS K12) — may reduce the bacteria responsible for volatile sulfur compounds, the primary cause of bad breath. Clinical trials have reported reductions in VSCs and improved odor scores using oral probiotic lozenges over 2 to 12-week periods. The evidence is promising but limited by small study sizes and short follow-up. Oral probiotics complement professional dental hygiene; consult a dentist to identify the underlying cause.
The strain with the most published evidence on halitosis is Streptococcus salivarius K12 (BLIS K12), which produces bacteriocins that specifically target VSC-producing oral bacteria. Lactobacillus salivarius and Lactobacillus reuteri have also been studied with positive findings in some trials. Look for the full strain designation on the label and published clinical evidence specific to that strain. Products listing only genus or species without alphanumeric strain codes cannot be evaluated against published research.
Clinical trials typically show measurable effects within 2 to 12 weeks of daily use, with most studies reporting significant VSC reductions within four weeks for participants using S. salivarius K12 or L. salivarius lozenges. It is not established how long effects persist after stopping; some data suggest rebound toward baseline when use is discontinued. Lozenges are typically used once daily after brushing at night, when saliva flow is lowest and oral residence time is longest.
In most people, bad breath originates in the mouth from VSC-producing bacteria. In some individuals, persistent malodor has a digestive origin: GERD, gut dysbiosis, or other gastrointestinal conditions can cause odors that arise from the stomach or intestines rather than the oral cavity. Oral probiotic lozenges are designed for the oral microbiome and would not address malodor originating in the gut. A healthcare provider can help determine whether breath concerns are oral or digestive in origin.
Bio-K+ does not claim that its products reduce or address bad breath. Bio-K+ probiotic products — fermented drinkables and capsules — are formulated and clinically validated for gut health applications only. The strains studied for halitosis, particularly S. salivarius K12, are distinct from Bio-K+'s proprietary gut strains and have independent clinical evidence for oral applications. Bio-K+ publishes this educational page as part of its oral microbiome science series.
Suis @biokplus et tague-nous pour être mentionné.e.
